Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1990-9-13
pubmed:abstractText
1. Glibenclamide, a sulphonylurea oral hypoglycaemic agent is a widely used antagonist of cromakalim-activated K+ channels in smooth muscle. 2. In isolated ring segments of the large circumflex coronary artery from the dog, glibenclamide (1-30 microM) caused a concentration-dependent reduction in both spontaneous isometric force and contractions induced by U46619, a thromboxane A2-mimetic. 3. Glibenclamide behaved as a competitive antagonist of U46619 with an estimated pKB (-log KB) value of 6.2 by Schild regression analysis (slope 1.07). 4. Glibenclamide (30 microM) was apparently selective since it had no effect on the concentration-contraction curves to endothelin-1, noradrenaline or KCl. 5. We suggest that this additional property of glibenclamide should be considered in any smooth muscle study where active force is raised by either the exogenous application or endogenous generation of thromboxane A2.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-13651579, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2427147, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2445740, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2452991, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2464055, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2470594, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2495353, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2497925, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2527074, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-2528466, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-6103047, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-6132635, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-6288415, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-6430377, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-6621711, http://linkedlifedata.com/resource/pubmed/commentcorrection/2143093-731426
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
100
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
375-8
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:2143093-15-Hydroxy-11 alpha,9..., pubmed-meshheading:2143093-Animals, pubmed-meshheading:2143093-Coronary Vessels, pubmed-meshheading:2143093-Dogs, pubmed-meshheading:2143093-Endothelins, pubmed-meshheading:2143093-Endothelium, Vascular, pubmed-meshheading:2143093-Female, pubmed-meshheading:2143093-Glyburide, pubmed-meshheading:2143093-Isometric Contraction, pubmed-meshheading:2143093-Male, pubmed-meshheading:2143093-Muscle, Smooth, Vascular, pubmed-meshheading:2143093-Muscle Contraction, pubmed-meshheading:2143093-Norepinephrine, pubmed-meshheading:2143093-Peptides, pubmed-meshheading:2143093-Potassium Chloride, pubmed-meshheading:2143093-Prostaglandin Endoperoxides, Synthetic, pubmed-meshheading:2143093-Receptors, Prostaglandin, pubmed-meshheading:2143093-Receptors, Thromboxane, pubmed-meshheading:2143093-Thromboxane A2, pubmed-meshheading:2143093-Tolbutamide
pubmed:year
1990
pubmed:articleTitle
Glibenclamide is a competitive antagonist of the thromboxane A2 receptor in dog coronary artery in vitro.
pubmed:affiliation
Baker Medical Research Institute, Prahran, Victoria, Australia.
pubmed:publicationType
Journal Article, In Vitro, Research Support, Non-U.S. Gov't